We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Wearable Hormone Monitor Enables At-Home Detection of Primary Aldosteronism

By HospiMedica International staff writers
Posted on 28 Aug 2026

Primary aldosteronism, a hormone disorder that affects up to one in five people with hypertension, increases risks of heart disease, stroke and diabetes. More...

Many cases are missed because routine testing is infrequent and hormone levels fluctuate over the day and night. Delayed or absent diagnosis leaves patients exposed to preventable cardiovascular harm. A new study shows that continuous, at-home hormone monitoring with a wearable can uncover hidden spikes that signal the condition earlier.

Researchers at the University of Bristol developed the U-RHYTHM wearable and evaluated it with collaborators at the University of Manchester, the University of Bergen, and partner institutions in Stockholm and Athens. The system enables 24-hour hormone profiling during normal daily activities, with the goal of revealing disease-related hormonal rhythms that conventional clinic-based testing may miss.

U-RHYTHM is a lightweight, waist-worn device about the size of a mobile phone. It samples hormones from the skin every 20 minutes while patients continue their usual activities and sleep overnight. This continuous sampling generates circadian hormone profiles that can then be analyzed computationally to identify abnormal patterns over time.

In a proof-of-concept study, 60 patients from Bristol, Bergen, Stockholm, and Athens were monitored over a single 24-hour period. Researchers tracked aldosterone together with the related steroids 18-hydroxycortisol and 18-oxocortisol. Rather than remaining persistently elevated, hormone levels showed repeated nocturnal bursts and daytime surges.

These fluctuations may help explain why single-time-point blood tests can miss cases and were most pronounced when disease involved only one adrenal gland. In patients with unilateral disease, the abnormal hormone pattern disappeared after surgical removal of the affected gland, supporting a direct link between the rhythm and the disorder. The findings were published in Science Translational Medicine in August 2026. The technology was adopted and further developed by the spinout company Dynamic Therapeutics in 2023.

“Primary aldosteronism is an important cause of high blood pressure and the most common cause of secondary hypertension we see in our blood pressure clinic. It could be affecting millions of people in the UK. However, due to the way hormones change during the day and the current complexity of the diagnostic process, diagnosis is often delayed or never made at all. In our study, patients were monitored at home during normal activity, and this allowed us to see how hormones changed over time in realistic settings. This approach could potentially revolutionize how we diagnose hypertension and ultimately reduce cardiovascular disease—particularly heart disease and strokes—that could have been prevented,” said Dr. Thomas Upton, clinical research fellow in automated sampling, clinical fellow at the University of Bristol and senior clinical fellow at Bristol Hospitals NHS Foundation Trust.

“By continuously monitoring hormones over 24 hours, we were able to reveal a previously hidden pattern of nocturnal hormone bursts. This gives us a much clearer understanding of the disease and could ultimately help doctors detect it earlier and treat patients more effectively. A more detailed mathematical and computational analysis of daily hormonal profiles could eventually also help uncover earlier and more subtle forms of the disease, opening new opportunities to improve outcomes for patients living with high blood pressure,” said Dr. Eder Zavala, UKRI Future Leader Fellow at the University of Manchester.

Related Links
University of Bristol 


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.